Torsades de Pointes Due to Drug Interaction between Disopyramide and Clarithromycin

Heart Disease

Volumn 1, Issue 4, 1999, Pages 206-207

  Choudhury, Lubna ^b   Grais, Ira Martin ^b   Passman, Rod Stuart ^a  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTI ARRHYTHMIA AGENTS; ANTIARRHYTHMIC AGENT; CLARITHROMYCIN; DISOPYRAMIDE; MACROLIDE;

AGED; ARTICLE; CASE REPORT; DRUG INTERACTION; FEMALE; HUMAN; IATROGENIC DISEASE; TORSADE DES POINTES;

AGED; ANTI-ARRHYTHMIA AGENTS; ANTIBIOTICS, MACROLIDE; CASE REPORT; CLARITHROMYCIN; DISOPYRAMIDE; DRUG INTERACTIONS; FEMALE; HUMAN; TORSADES DE POINTES;

EID: 0033188564     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Ragosta, M, Weihl AD, Rosenfield LE. Potentially fatal interaction between erythromycin and disopyramide. Am J Med 1989;86:465-466.
2. Gitler B, Berger LS, Buffa SD. Torsades de pointes induced by erythromycin. Chest 1994;105:368-372.
3. Guelon D, Bedock B, Charrier C, Harberer J. QT prolongation and recurrent torsades de pointes during erythromycin lactobionate infusion. Am J Cardiol 1986;58:666.
4. Nahata M. Drug interactions with azithromycin and the macrolides: an overview. J Antimicrobial Chemother 1996;37(Suppl C):133-142.
5. Periti P, Mazzei T, Mini E, Novelli A. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992;23:106-131.
6. Lee KL, Man-Hong J, Tang SC, Yau-Ting T. QT prolongation and torsades de pointes associated with clarithromycin. Am J Med 1998;104:395-396.
7. Sekkarie MA. Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin. Am J Kidney Dis 1997;30:437-439.
8. Wysowski DK, Bascanyi J. Cisapride and faral arrhythmia. N Engl J Med 1996; 335:290-291.
9. Paar D, Terjung B, Sauerbruch T. Life-threatening interaction between clarithromycin and disopyramide. Lancet 1997;349:326-327.
10. Molnar J, Zhang H, Weiss J, Ehlert F, Rosenthal J. Diurnal pattern of QTC interval: how long is prolonged? Possible relation to circadian triggers of cardiovascular events. J Am Coll Cardiol 1996;28:799-801.
11. Morganroth J, Brozovich F, McDonald J, Jacobs R. Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am J Cardiol 1991;67:774-775.
12. Kadish A, Weisman H, Veltri E, Epstein A, Slepian M, Levine J. Paradoxical effects of exercise on the QT interval in patients with polymorphic ventricular tachycardia receiving type Ia antiarrhythmic agents. Circulation 1990;81:9-14.
13. Chu SY, Wilson DS, Deaton RL, et al. Single-and multiple-dose pharmacokinetics of clarithromycin, a new macrolide antimicrobial. J Clin Pharmacol 1993;33:719-726.
14. Nattel S, Ranger S, Talajic M, et al. Erythromycin-induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiological mechanism. Am J Med 1990;89:235-238.
15. Rubart M, Pressler ML, Pride HP, Zipes DP. Electrophysiological mechanisms in a canine model of erythromycin-associatcd long QT syndrome. Circulation 1993;88:1832-1844.
16. Sessler CN, Cohen MD. Cardiac arrhythmias during theophylline toxicity: a prospective continuous electrocardiographic study. Chest 1990;98:672-678.